Skip to content
Clinical Trials – home

Azienda Ospedaliera Universitaria Universita' Degli Studi Della Campania Luigi Vanvitelli

Verified siteinfo

Italy Piazza Luigi Miraglia 2, 80138 Naples, Italy

  • 112 trials recruiting
  • Colorectal cancer metastatic · Non-small cell lung cancer · Chronic kidney disease
  • Adults and children

About Specializations

Azienda Ospedaliera Universitaria Universita' Degli Studi Della Campania Luigi Vanvitelli in Naples, Italy specialises in clinical trials of conditions such as Colorectal cancer metastatic, Non-small cell lung cancer, Chronic kidney disease, Non-small cell lung cancer metastatic, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology and Hematology

At Azienda Ospedaliera Universitaria Universita' Degli Studi Della Campania Luigi Vanvitelli, the strongest research activity is in neoplasms and hemic and lymphatic diseases, with many studies focused on common and hard-to-treat cancers such as non-small cell lung cancer, colorectal cancer, gastric cancer, and head and neck squamous cell carcinoma. These trials are designed to test new treatment options, compare them with current standards, and improve outcomes for patients with advanced or recurrent disease.

  • Testing new cancer therapies for advanced solid tumors and metastatic disease
  • Evaluating treatment effectiveness in lung, gastrointestinal, and head and neck cancers
  • Studying personalized approaches for biomarker-selected tumors

The UOC Oncoematologia also participates in studies for blood cancers and related disorders, reflecting a broad oncology program with a strong translational focus.

Immunology and Autoimmune Diseases

A major part of the site’s portfolio covers immune system diseases and inflammatory conditions, including multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, juvenile idiopathic arthritis, and myasthenia gravis. These trials aim to better control disease activity, reduce relapses, and assess whether newer therapies can improve long-term management compared with established treatments.

  • Exploring therapies for relapsing and progressive multiple sclerosis
  • Assessing new options for lupus, rheumatoid arthritis, and juvenile arthritis
  • Studying treatments that may improve symptoms in myasthenia gravis

Research in this area combines symptom control with the search for safer, more durable treatment strategies.

Gastroenterology and Liver Disease

The site is active in digestive system diseases and liver-related research, with studies in Crohn's disease, ulcerative colitis, pouchitis, esophageal disorders, hepatocellular carcinoma, and biliary tract cancer. These trials are mainly aimed at improving disease control, supporting remission, and evaluating new treatment approaches for both inflammatory and malignant conditions of the gastrointestinal tract.

  • Testing therapies for inflammatory bowel disease and chronic pouchitis
  • Studying treatments for liver and biliary cancers
  • Evaluating options for esophageal and gastric cancers

This area shows a strong mix of cancer research and chronic digestive disease management.

Neurology and Neurodegenerative Disorders

Clinical trials also address nervous system diseases, including Parkinson's disease, Alzheimer’s disease, amyotrophic lateral sclerosis, epilepsy, and Lewy body dementia. The main goal is to evaluate therapies that may slow progression, improve daily functioning, or ease symptoms in conditions with major long-term impact on patients and families.

  • Investigating treatments for movement disorders and cognitive decline
  • Studying therapies for ALS and refractory epilepsy
  • Assessing new approaches for dementia-related symptoms

This research supports both symptom relief and disease-modifying strategies in complex neurological conditions.

Dermatology, Allergy, and Musculoskeletal Care

Another important research theme includes skin and connective tissue diseases, musculoskeletal diseases, and related inflammatory disorders such as atopic dermatitis, psoriasis, hidradenitis suppurativa, prurigo nodularis, and psoriatic arthritis. Trials in this group are focused on reducing inflammation, improving skin symptoms, and helping patients achieve better day-to-day quality of life.

  • Evaluating new treatments for chronic inflammatory skin diseases
  • Studying therapies for psoriatic and rheumatologic conditions
  • Testing approaches to improve long-term symptom control

The research portfolio here reflects a strong interest in immune-driven skin and joint disease.

Kidney, Metabolic, and Cardiovascular Research

The site also runs trials in nutritional and metabolic diseases, cardiovascular diseases, and kidney disease, including chronic kidney disease, immunoglobulin A nephropathy, type 2 diabetes, hypertension, and myocardial infarction. These studies are designed to slow disease progression, reduce complications, and evaluate whether new therapies can improve long-term health outcomes.

  • Studying treatments to protect kidney function and delay progression
  • Evaluating therapies for diabetes and high blood pressure
  • Assessing cardiovascular risk reduction strategies

This area adds an important chronic disease dimension to the site’s broader clinical trial program.

Eye Diseases and Rare Conditions

A smaller but notable set of studies focuses on eye diseases and other rare disorders, including geographic atrophy, age-related macular degeneration, retinitis pigmentosa, and inherited syndromes such as neurofibromatosis type 1 and Turner syndrome. The purpose of these trials is to improve diagnosis, preserve function, and explore innovative treatments for conditions with limited options.

  • Testing therapies for degenerative retinal disease
  • Studying rare genetic and developmental disorders
  • Exploring approaches that may preserve vision or function

These studies highlight the site’s involvement in specialized research beyond common adult diseases.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Site location
Piazza Luigi Miraglia 280138 NaplesItaly
Recruiting now
112 trials
Conditions studied
162
Partner status
Verified site

More sites in NaplesItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

285 clinical trials

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Phase III Randomized Study of Balcinrenone and Dapagliflozin Versus Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease Stage 3b‑4

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

A Randomized Trial of lu af28996 dh1 to Reduce Motor Fluctuations in Adults with Parkinson’s Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:LU AF28996 DH1
  • Sponsor:H. Lundbeck A/S

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ZL-1310
  • Sponsor:Zai Lab (US) LLC

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

A study to evaluate the effectiveness and safety of pridopidine hydrochloride in patients with amyotrophic lateral sclerosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pridopidine hydrochloride
  • Sponsor:Ferrer Internacional S.A.

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Psoriasis

Recruiting

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Summit Therapeutics Inc.

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.